Topics

AbbVie to Buy Allergan for $63 Billion

23:08 EDT 26 Jun 2019 | CHEManager

In a deal expected to close early next year, US biopharma AbbVie is buying troubled Botox manufacturer Allergan for $63 billion in cash and shares. The acquisition is the second largest to be proposed in the drugs sector this year, behind BristolMyersSquibb’s takeover of Celgene for $74 billion.

Original Article: AbbVie to Buy Allergan for $63 Billion

NEXT ARTICLE

More From BioPortfolio on "AbbVie to Buy Allergan for $63 Billion"

Quick Search

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...